Intrasense SA AI Stock Analysis
Want to see FR:ALINS full AI Analyst Report?
Intrasense SA (ALINS) AI Stock Analysis
Intrasense SA
(Paris:ALINS)
Intrasense SA receives a critically low score reflecting existential financial distress. Financial performance dominance (40% weight) is the primary driver: the company is burning cash at accelerating rates (-€5.9M in 2024), equity is nearly depleted at €1.65M, and revenues are collapsing with negative margins across all profitability measures. Technical analysis (30% weight) contributes marginally better, showing neutral-to-weak technicals with price below all major moving averages. Valuation (30% weight) provides no meaningful support, with negative earnings rendering P/E analysis impossible and no dividend yield. Without evidence of operational stabilization, capital restructuring, or strategic pivot, this stock represents substantial distress risk unsuitable for most investors.
Intrasense SA (ALINS) vs. iShares MSCI France ETF (EWQ)
- Market Cap
- EUR 10.56M
- Dividend Yield
- ―
- Average Volume (3M)
- 183.72K
- Price to Earnings (P/E)
- -0.7
- Beta (1Y)
- -0.13
- Revenue Growth
- -24.18%
- EPS Growth
- -120.44%
- Country
- France
- Employees
- 76
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Medical - Healthcare Information Services
Intrasense SA Business Overview & Revenue Model
Company Description
Established in 2004 and headquartered in Montpellier, France, Intrasense S.A. specializes in the global development of sophisticated software for visualizing and analyzing diverse medical imaging data, marketed under its Myrian brand. The company's o...
How the Company Makes Money
Intrasense generates revenue primarily through the sale and licensing of its software solutions to healthcare institutions, including hospitals and imaging centers. The company employs a subscription-based model for its software, which provides a rec...
Intrasense SA Financial Statement Overview
Summary
Intrasense SA exhibits severe financial distress across all dimensions. Income statement shows catastrophic margins (gross profit -170%, net profit -252%) with 32% revenue decline year-over-year. Balance sheet equity has eroded to €1.65M against €6.03M liabilities, yielding deeply negative ROE of -342%. Cash flow deterioration is critical, with free cash flow worsening 19% to -€5.9M in 2024. Financing inflows are masking unsustainable cash burn. Without operational turnaround or capital infusion, viability is at risk.
Income Statement
8Very NegativeBalance Sheet
14Very NegativeCash Flow
6Very Negative| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 2.65M | 2.25M | 3.31M | 3.79M | 4.19M | 3.44M |
| Gross Profit | -6.07M | -3.81M | -885.00K | -1.15M | -1.05M | -454.00K |
| EBITDA | -5.37M | -4.60M | -2.68M | -2.72M | -611.00K | -217.00K |
| Net Income | -6.48M | -5.66M | -3.58M | -3.42M | -1.20M | -704.00K |
Balance Sheet | ||||||
| Total Assets | 9.19M | 7.68M | 10.45M | 6.51M | 8.77M | 6.36M |
| Cash, Cash Equivalents and Short-Term Investments | 1.44M | 930.00K | 4.55M | 1.41M | 4.76M | 2.59M |
| Total Debt | 1.37M | 1.58M | 1.49M | 2.06M | 1.93M | 2.26M |
| Total Liabilities | 10.36M | 6.03M | 3.17M | 4.50M | 3.78M | 4.21M |
| Stockholders Equity | -1.16M | 1.65M | 7.29M | 2.01M | 4.99M | 2.15M |
Cash Flow | ||||||
| Free Cash Flow | -6.50M | -5.94M | -4.97M | -3.48M | -1.50M | -1.08M |
| Operating Cash Flow | -4.62M | -3.73M | -3.05M | -2.00M | -948.00K | -481.00K |
| Investing Cash Flow | -1.86M | -2.21M | -1.93M | -1.49M | -555.00K | -551.00K |
| Financing Cash Flow | 6.61M | 2.33M | 8.10M | 98.00K | 3.62M | 2.71M |
Intrasense SA Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For FR:ALINS, the sentiment is Negative. The current price of 0.20 is below the 20-day moving average (MA) of 0.20, below the 50-day MA of 0.22, and below the 200-day MA of 0.23, indicating a bearish trend. The MACD of -0.00 indicates Negative momentum. The RSI at 41.92 is Neutral, neither overbought nor oversold. The STOCH value of 43.29 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for FR:ALINS.
Intrasense SA Peers Comparison
Overall Rating
FR:ALCGM60Neutral
FR:ALTHE46Neutral
FR:ALIKO45Neutral
FR:ALMDT43Neutral
FR:ALINS21Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| 60Neutral | EUR 124.66M | -8.49 | -5.44% | ― | -0.98% | ― | |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| 46Neutral | EUR 42.94M | -5.62 | 453.10% | ― | -16.98% | 20.31% | |
| 45Neutral | EUR 22.89M | -5.31 | -22.49% | ― | 37.28% | 7.83% | |
| 43Neutral | EUR 209.76M | -3.48 | 271.64% | ― | 2.16% | -5.26% | |
| 21Underperform | EUR 10.56M | -0.74 | 148.60% | ― | -24.18% | -120.44% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| FR:ALINS | Intrasense SA | 0.20 | -0.06 | -21.87% | |
| FR:ALCGM | Cegedim SA | 9.09 | -2.91 | -24.25% | |
| FR:ALTHE | Theraclion SA | 0.58 | -0.07 | -10.19% | |
| FR:ALDMS | Diagnostic Medical Systems | 0.90 | -0.37 | -29.13% | |
| FR:ALIKO | Ikonisys SA | 1.45 | 0.02 | 1.40% | |
| FR:ALMDT | Median Technologies | 4.28 | 1.49 | 53.41% |
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Jan 15, 2026
